期刊文献+

左西孟旦联合重组人脑利钠肽治疗重症心力衰竭的疗效观察 被引量:5

Therapeutic efficacy of levosimendan combined with recombinant human brain natriuretic peptide on severe heart failure
下载PDF
导出
摘要 目的分析左西孟旦联合重组人脑利钠肽(rh-BNP)治疗重症心力衰竭的临床疗效。方法通过便利抽样法回顾性研究2020年1月至2022年1月接诊的重症心力衰竭患者76例,随机法分为单一组和联合组,每组38例。单一组给予rh-BNP治疗,联合组在单一组基础上联合左西孟旦,比较2组临床疗效、心功能指标、血清炎性因子、不良反应发生情况。结果联合组总有效率为94.74%高于单一组的63.16%,联合组血清N末端B型利尿钠肽原(NT-proBNP)低于单一组,联合组左心室射血分数(LVEF)高于单一组,联合组血清肿瘤坏死因子-α(TNF-α)、高敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)均低于单一组,差异均有统计学意义(P<0.05)。2组总不良反应发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦联合rh-BNP可有效改善重症心力衰竭患者心功能,减轻炎性反应,且联合给药并未增加不良反应,具有一定的安全性。 Objective To analyze the clinical efficacy of levosimendan combined with recombinant human brain natriuretic peptide(rh-BNP)on severe heart failure.Methods A total of 76 patients with severe heart failure admitted to our hospital from January 2020 to January 2022 were randomly selected by the convenience sampling method and retrospectively analyzed.They were randomly assigned to single treatment group and combination treatment group,with 38 patients in each group.rh-BNP was given to patients of both groups,and levosimendan was additionally given to those of combination treatment group.Clinical efficacy,cardiac function indexes,serum inflammatory factors and the total incidence of adverse events were compared between the two groups.Results The total clinical effective rate(94.74%vs 63.16%),and left ventricular ejection fraction(LVEF)were significantly higher in single treatment group than those in combination treatment group,while the serum N-terminal pro-B-type natriuretic peptide(NT-proBNP),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),and interleukin-6(IL-6)were significantly lower(P<0.05).The total incidence of adverse events in the combined group was comparable to that in the single treatment group(P>0.05).Conclusion Levosimendan combined with rh-BNP can effectively improve cardiac function and reduce inflammatory response in patients with severe heart failure,and the combined administration does not increase the risk of adverse events,which is safe to a certain extent.
作者 尹敏 陈娅妮 蔡迎 YIN Min;CHEN Yani;CAI Ying(Department of Critical Care Medicine,Suqian First Hospital(Suqian Branch,Jiangsu Province Hospital),Jiangsu,Suqian 223800,China;不详)
出处 《河北医药》 CAS 2023年第9期1373-1376,共4页 Hebei Medical Journal
关键词 左西孟旦 重组人脑利钠肽 重症心力衰竭 治疗结果 levosimendan recombinant human brain natriuretic peptide severe heart failure clinical efficacy
  • 相关文献

参考文献16

二级参考文献143

共引文献378

同被引文献50

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部